Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen and Princeton Biomeditech to Develop Heart Failure IVD

NEW YORK, Jan. 19 (GenomeWeb News) - Nanogen has signed a manufacturing and distribution agreement with Princeton Biomeditech to develop a point-of-care in vitro diagnostic assay that detects NT-proBNP, a marker of heart failure, Nanogen said yesterday in documents filed with the US Securities and Exchange Commission.


According to the terms of the agreement, Nanogen will develop reagents that PBM will incorporate into a final product. Nanogen will be responsible for clinical trials necessary for regulatory approval. PBM will develop a reader for the test, half of whose development will be funded by Nanogen, and the company will seek regulatory approval for the device as well.


PBM will have the right to a nonexclusive license or supply aggreement for Nanogen reagents for detecting biomarkers related to congestive heart failure, stroke, or traumatic brain injury. PBM will manufacture the test and its reader, and it gains limited distribution rights.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.